IRX5183

A Phase 1 Study of IRX195183, a RARĪ±-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML Ambinder AJ, Norsworthy K, Hernandez D, Palau L, Paun B, Duffield A, Chandraratna R, Sanders M, Varadhan R, Jones RJ, Douglas Smith B, Ghiaur G. Front Oncol. 2020 Oct 23;10:587062. doi: 10.3389/fonc.2020.587062. PMID: 33194741; PMCID: PMC7645224

Overcoming microenvironment-mediated protection from ATRA using CYP26-resistant retinoids. Leukemia Hernandez D, Palau L, Norsworthy K, Anders NM, Alonso S, Su M, Petkovich M, Chandraratna R, Rudek MA, Smith BD, Jones RJ, Ghiaur G. . 2020 Nov;34(11):3077-3081. doi: 10.1038/s41375-020-0790-4. Epub 2020 Mar 9. PMID: 32152463; PMCID: PMC7483812

Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance Alonso S, Hernandez D, Chang YT, Gocke CB, McCray M, Varadhan R, Matsui WH, Jones RJ, Ghiaur G. J Clin Invest. 2016 Dec 1;126(12):4460-4468. doi: 10.1172/JCI88152. Epub 2016 Oct 24. PMID: 27775549; PMCID: PMC5127663